Clearside Biomedical (NASDAQ:CLSD) Issues Earnings Results

Clearside Biomedical (NASDAQ:CLSD) posted its quarterly earnings data on Friday. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.47), Zacks reports. The business had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.09 million.

Clearside Biomedical Stock Performance

Shares of CLSD stock opened at $3.82 on Friday. Clearside Biomedical has a fifty-two week low of $3.32 and a fifty-two week high of $17.10. The stock’s fifty day moving average price is $4.06 and its two-hundred day moving average price is $7.93. The company has a market cap of $20.01 million, a PE ratio of -0.69 and a beta of 2.04.

Analysts Set New Price Targets

CLSD has been the subject of a number of recent research reports. Stifel Nicolaus cut shares of Clearside Biomedical from a “buy” rating to a “hold” rating and set a $30.00 target price for the company. in a research report on Friday, July 18th. Weiss Ratings assumed coverage on shares of Clearside Biomedical in a research note on Saturday, November 1st. They issued a “sell (e+)” rating for the company. Chardan Capital lowered shares of Clearside Biomedical from a “buy” rating to a “neutral” rating in a research report on Friday, July 18th. HC Wainwright cut shares of Clearside Biomedical from a “buy” rating to a “neutral” rating and set a $75.00 target price on the stock. in a report on Friday, July 18th. Finally, Wall Street Zen upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $63.00.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.